News

The US Is Running Out of a Key Cancer Drug and Has Asked India to Fix It — This Is What Being the Pharmacy of the World Actually Means

By Darshan S, Editor · 07 July,2026 · 2 min read

Darshan S, Editor — The US Is Running Out of a Key Cancer Drug and Has Asked India to Fix It — This Is What Being the Pharmacy of the World Actually Means

Summary

  • US FDA Asks India to Fix Ifosfamide Cancer Drug Shortage: Zydus, Cipla, Alkem, and Aurobindo Among Front-Runners
  • The US FDA asked the Indian Drug Manufacturers' Association to identify Indian manufacturers capable of supplying ifosfamide injections to address an ongoing US cancer drug shortage, with Zydus, Cipla, Alkem, and Aurobindo among front-runners.

"The US FDA is interested in information from manufacturers that are currently producing or have the capability to produce ifosfamide injection 1 g and/or 3 g to help address an ongoing drug shortage in the US. IDMA has received this communication and has alerted Indian pharmaceutical companies to respond. India has answered calls like this before. We will answer this one too."

The United States Food and Drug Administration's India Office transmitted a formal communication to the Indian Drug Manufacturers' Association on June 18, 2026, requesting assistance in identifying pharmaceutical companies capable of supplying ifosfamide injection in 1 gram and 3 gram strengths to the US market in order to address an ongoing drug shortage that has listed multiple ifosfamide product strengths as unavailable, in limited supply, or temporarily on backorder.

The shortage's proximate cause is GMP compliance issues at Baxter International, the primary US supplier of ifosfamide injection, whose production has resumed but remains below the level required to meet market demand. 'We are working urgently with our manufacturing partner, and in alignment with regulatory authorities, as well as other relevant stakeholders, to restore supply as quickly and responsibly as possible,' a Baxter spokesperson told Mint. The FDA has estimated supplies could begin recovering by October 2026 — but the interim gap requires emergency supply from alternative manufacturers.

Why Ifosfamide Matters Clinically

Ifosfamide is an alkylating chemotherapy agent with a long history of clinical use in oncology. It is indicated for the treatment of testicular cancer (as part of combination regimens including cisplatin and etoposide for germ cell tumours), bladder cancer, and lung cancer, among other malignancies. In testicular cancer particularly, ifosfamide-containing salvage regimens are a cornerstone of treatment for patients who have failed first-line cisplatin-based chemotherapy — a population where the drug's availability can be directly life-determining.

Drug shortages of established chemotherapy agents create cascading clinical problems. Oncologists must delay treatment cycles while seeking alternative suppliers, substitute less-effective regimens in some patients, or in some cases defer treatment for patients who would otherwise be receiving ifosfamide. Each of these scenarios has potential adverse effects on patient outcomes — particularly for patients in time-sensitive salvage treatment situations.

India's Front-Runner Candidates

Viranchi Shah, National Spokesperson of the Indian Drug Manufacturers' Association, confirmed to the Economic Times that Zydus Lifesciences, Cipla, Alkem, and Aurobindo Pharma's GLS are among the frontrunners to supply ifosfamide given their existing US market presence and established manufacturing capability for the molecule. The IDMA is not party to the commercial negotiations — it is acting as a communication conduit, alerting its member companies to the FDA's request so that individual companies can engage directly with the FDA and with potential buyers.

The FDA's communication specified a preference for manufacturers at FDA-registered facilities — a qualification that reduces the field to Indian manufacturers who already have US-registered manufacturing sites that have been inspected by the FDA and are in good regulatory standing. However, the communication noted that compliant non-registered facilities would also be considered, reflecting the urgency of the shortage.

Analyst commentary across multiple platforms (Silicon India, Dailyhunt) identified additional Indian companies as potential beneficiaries: Intas Pharmaceuticals and Dr Reddy's Laboratories were noted as particularly relevant given their advanced sterile injectable facilities and oncology injectable experience; Lupin's high-potency oncology manufacturing and Sun Pharma's scale in oncology were identified as further strengths.

The Operation Epic Fury Context

The Hormuz disruption deepened the ifosfamide shortage by further stressing pharmaceutical supply chains already under GMP-related pressure. Active pharmaceutical ingredient imports from non-Gulf sources, logistics rerouting adding weeks to supply timelines, and the general pharmaceutical supply chain uncertainty of the conflict period all contributed to supply-demand mismatches for critical medicines including ifosfamide.

The FDA's decision to formally reach out to India — rather than to European or other Asian pharmaceutical manufacturers — reflects India's established position as the world's most significant supplier of generic pharmaceutical products to the US market and the country with the largest number of US FDA-approved manufacturing facilities outside the United States. India already supplies approximately 30% of the US generic drug market by volume. When the US has a critical drug shortage, asking India is the logical first call.

"BHC Perspective"

At Bengaluru Health Community, the ifosfamide shortage story is a moment where India's 'pharmacy of the world' positioning becomes viscerally real. Cancer patients in the United States are depending on Indian pharmaceutical companies to supply the chemotherapy they need. For BHC founders in pharmaceutical manufacturing, API production, or sterile injectables — this is the demand environment you are building for. The US market's dependence on Indian pharmaceutical manufacturing is structural, not incidental.

Frequently Asked Questions

Q: Why is there an ifosfamide shortage in the US?
A: GMP compliance issues at Baxter International, the primary US ifosfamide supplier, reduced production below market demand. The shortage was deepened by Operation Epic Fury's pharmaceutical supply chain disruption. Multiple ifosfamide strengths have been listed as unavailable or in limited supply since June 12, 2026.

Q: Which Indian companies are frontrunners to supply?
A: Viranchi Shah (IDMA National Spokesperson) confirmed Zydus Lifesciences, Cipla, Alkem, and Aurobindo Pharma's GLS as frontrunners given US market presence and ifosfamide manufacturing capability. Analysts also cited Intas, Dr Reddy's, Lupin, and Sun Pharma for their oncology injectable capabilities.

Q: Why did the FDA ask India specifically?
A: India is the world's largest supplier of generic pharmaceutical products to the US market (~30% of US generic volume) and has the most US FDA-approved manufacturing facilities outside the United States. When a critical drug shortage requires emergency supply, India is the logical and most capable source.